Novel metabolic biomarkers of cardiovascular disease

Majken K. Jensen, Monica L. Bertoia, Leah E. Cahill, Isha Agarwal, Eric B. Rimm, Kenneth J. Mukamal

Research output: Contribution to journalReview articlepeer-review

85 Citations (Scopus)

Abstract

Coronary heart disease (CHD) accounts for one in every six deaths in US individuals. Great advances have been made in identifying important risk factors for CHD, such as hypertension, diabetes mellitus, smoking and hypercholesterolaemia, which have led to major developments in therapy. In particular, statins represent one of the greatest successes in the prevention of CHD. While these standard risk factors are important, an obvious opportunity exists to take advantage of ongoing scientific research to better risk-stratify individuals and to identify new treatment targets. In this Review, we summarize ongoing scientific research in a number of metabolic molecules or features, including lipoproteins, homocysteine, calcium metabolism and glycaemic markers. We evaluate the current state of the research and the strength of evidence supporting each emerging biomarker. We also discuss whether the associations with CHD are strong and consistent enough to improve current risk stratification metrics, and whether these markers enhance our understanding of the underlying biology of CHD and thus point towards new treatment options.

Original languageEnglish
Pages (from-to)659-672
Number of pages14
JournalNature Reviews Endocrinology
Volume10
Issue number11
DOIs
Publication statusPublished - Nov 25 2014
Externally publishedYes

ASJC Scopus Subject Areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'Novel metabolic biomarkers of cardiovascular disease'. Together they form a unique fingerprint.

Cite this